Table 3.
Cox regression analysis for OS, PFS, and hPFS without interaction terms
| Univariable | p value | Multivariable | p value | |
|---|---|---|---|---|
| Overall survival (n = 496) | ||||
| Age < 65 years | 0.73 [0.62–0.86] | < 0.001 | 1.01 [0.73–1.39] | 0.95 |
| ASA > II | 0.95 [0.80–1.13] | 0.56 | 1.08 [0.79–1.46] | 0.63 |
| Location primary tumor | ||||
| Right-sided | Reference | – | Reference | – |
| Left-sided | 0.84 [0.69–1.03] | 0.10 | 0.83 [0.59–1.18] | 0.31 |
| Rectum | 0.83 [0.66–1.04] | 0.11 | 0.86 [0.57–1.29] | 0.46 |
| Preoperative systemic CTx | 1.75 [1.40–2.19] | < 0.001 | 1.67 [1.13–2.47] | < 0.01 |
| Number of CRLM | 1.09 [1.06–1.12] | < 0.001 | 1.10 [1.04–1.16] | < 0.01 |
| Diameter of largest CRLM (cm) | 1.04 [1.02–1.07] | < 0.01 | 1.08 [1.03–1.14] | < 0.001 |
| Preoperative CEA (before chemo) | 1.00 [1.00–1.00] | 0.76 | 1.00 [1.00–1.00] | 0.63 |
| Disease-free interval (months) | 1.00 [0.99–1.00] | 0.54 | 1.00 [0.98–1.01] | 0.51 |
| Nodal status primary tumor | 1.45 [1.22–1.73] | < 0.001 | 2.01 [1.42–2.83] | < 0.001 |
| R1 resection | 1.68 [1.36–2.07] | < 0.001 | 1.53 [1.01–2.31] | 0.04 |
| KRAS mutated | 1.71 [1.32–2.21] | < 0.001 | 1.63 [1.20–2.22] | < 0.01 |
| dHGP (vs. non-dHGP) | 0.67 [0.54–0.82] | < 0.001 | 0.49 [0.32–0.73] | < 0.001 |
| HAIP chemotherapy | 0.62 [0.50–0.76] | < 0.001 | 0.61 [0.45–0.82] | < 0.001 |
| Progression-free survival | ||||
| Age < 65 years | 0.97 [0.84–1.13] | 0.73 | 1.29 [0.98–1.70] | 0.07 |
| ASA >II | 0.92 [0.80–1.07] | 0.29 | 1.32 [1.02–1.71] | 0.04 |
| Location primary tumor | ||||
| Right-sided | Reference | – | Reference | – |
| Left-sided | 1.08 [0.90–1.28] | 0.43 | 1.14 [0.84–1.54] | 0.39 |
| Rectum | 1.07 [0.87–1.30] | 0.52 | 1.25 [0.88–1.76] | 0.21 |
| Preoperative systemic CTx | 1.83 [1.51–2.22] | < 0.001 | 1.34 [0.97–1.85] | 0.08 |
| Number of CRLM | 1.13 [1.10–1.15] | < 0.001 | 1.16 [1.10–1.21] | < 0.001 |
| Diameter of largest CRLM (cm) | 1.01 [0.99–1.04] | 0.31 | 1.05 [1.00–1.10] | 0.05 |
| Preoperative CEA (before chemo) | 1.00 [1.00–1.00] | 0.86 | 1.00 [1.00–1.00] | 0.36 |
| Disease-free interval (months) | 0.99 [0.99–1.00] | < 0.001 | 0.99 [0.98–1.01] | 0.28 |
| Nodal status primary tumor | 1.36 [1.17–1.58] | < 0.001 | 1.75 [1.33–2.31] | < 0.001 |
| R1 resection | 1.56 [1.29–1.89] | < 0.001 | 1.19 [0.82–1.73] | 0.36 |
| KRAS mutated | 1.40 [1.14–1.73] | < 0.01 | 1.41 [1.09–1.82] | < 0.01 |
| dHGP (vs. non-dHGP) | 0.64 [0.53–0.76] | < 0.001 | 0.72 [0.52–0.99] | 0.05 |
| HAIP chemotherapy | 0.53 [0.45–0.64] | < 0.001 | 0.47 [0.36–0.60] | < 0.001 |
| Hepatic progression-free survival | ||||
| Age < 65 years | 0.73 [0.62–0.86] | < 0.001 | 1.01 [0.73–1.39] | 0.95 |
| ASA >II | 0.95 [0.80–1.13] | 0.56 | 1.08 [0.79–1.46] | 0.63 |
| Location primary tumor | ||||
| Right-sided | Reference | – | Reference | – |
| Left-sided | 0.84 [0.69–1.03] | 0.10 | 0.83 [0.59–1.18] | 0.31 |
| Rectum | 0.83 [0.66–1.04] | 0.11 | 0.86 [0.57–1.29] | 0.46 |
| Preoperative systemic CTx | 1.75 [1.40–2.19] | < 0.001 | 1.67 [1.13–2.47] | < 0.01 |
| Number of CRLM | 1.09 [1.06–1.12] | < 0.001 | 1.10 [1.04–1.16] | < 0.01 |
| Diameter of largest CRLM (cm) | 1.04 [1.02–1.07] | < 0.01 | 1.08 [1.03–1.14] | < 0.001 |
| Preoperative CEA (before chemo) | 1.00 [1.00–1.00] | 0.76 | 1.00 [1.00–1.00] | 0.63 |
| Disease-free interval (months) | 1.00 [0.99–1.00] | 0.54 | 1.00 [0.98–1.01] | 0.51 |
| Nodal status primary tumor | 1.45 [1.22–1.73] | < 0.001 | 2.01 [1.42–2.83] | < 0.001 |
| R1 resection | 1.68 [1.36–2.07] | < 0.001 | 1.53 [1.01–2.31] | 0.04 |
| KRAS mutated | 1.71 [1.32–2.21] | < 0.001 | 1.63 [1.20–2.22] | < 0.01 |
| dHGP (vs. non-dHGP) | 0.67 [0.54–0.82] | < 0.001 | 0.49 [0.32–0.73] | < 0.001 |
| HAIP chemotherapy | 0.62 [0.50–0.76] | < 0.001 | 0.61 [0.45–0.82] | < 0.001 |
Bold values are statistically significant (p < 0.05)